These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 1912033)

  • 1. Hirudin, a new therapeutic tool?
    Bichler J; Fritz H
    Ann Hematol; 1991 Aug; 63(2):67-76. PubMed ID: 1912033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hirudin: clinical potential of a thrombin inhibitor.
    Johnson PH
    Annu Rev Med; 1994; 45():165-77. PubMed ID: 8198374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent.
    Fareed J; Walenga JM; Iyer L; Hoppensteadt D; Pifarre R
    Blood Coagul Fibrinolysis; 1991 Feb; 2(1):135-47. PubMed ID: 1772981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
    Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H
    Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
    Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model.
    Walenga JM; Bakhos M; Messmore HL; Koza M; Wallock M; Orfei E; Fareed J; Pifarre R
    Blood Coagul Fibrinolysis; 1991 Feb; 2(1):105-11. PubMed ID: 1772977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of heparin-resistant microarterial thrombosis by recombinant hirudin: a specific thrombin inhibitor.
    Arnljots B; Bergqvist D
    Plast Reconstr Surg; 1995 Apr; 95(5):894-900. PubMed ID: 7708874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin.
    Monreal M; Costa J; Salva P
    Drugs Aging; 1996 Mar; 8(3):171-82. PubMed ID: 8720743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
    Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
    Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
    Haskel EJ; Prager NA; Sobel BE; Abendschein DR
    Circulation; 1991 Mar; 83(3):1048-56. PubMed ID: 1900222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin.
    Bates SM; Weitz JI
    Am J Cardiol; 1998 Oct; 82(8B):12P-18P. PubMed ID: 9809887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease.
    Cannon CP; Maraganore JM; Loscalzo J; McAllister A; Eddings K; George D; Selwyn AP; Adelman B; Fox I; Braunwald E
    Am J Cardiol; 1993 Apr; 71(10):778-82. PubMed ID: 8456753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
    Rao AK; Sun L; Chesebro JH; Fuster V; Harrington RA; Schwartz D; Gallo P; Matos D; Topol EJ
    Circulation; 1996 Nov; 94(10):2389-95. PubMed ID: 8921778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hirudin and hirudin fragments].
    Deschamps A; Samama M
    Ann Cardiol Angeiol (Paris); 1992 Oct; 41(8):A49-53. PubMed ID: 1298182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model.
    Deschênes I; Finkle CD; Winocour PD
    Thromb Haemost; 1998 Jul; 80(1):186-91. PubMed ID: 9684808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The direct thrombin inhibitor hirudin.
    Greinacher A; Warkentin TE
    Thromb Haemost; 2008 May; 99(5):819-29. PubMed ID: 18449411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hirudins for prophylaxis and treatment of venous thromboembolism.
    Prisco D; Falciani M; Antonucci E; Gensini GF
    Semin Thromb Hemost; 2001 Oct; 27(5):543-9. PubMed ID: 11668426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
    Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
    J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
    Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
    Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene.
    Rubens FD; Weitz JI; Brash JL; Kinlough-Rathbone RL
    Thromb Haemost; 1993 Feb; 69(2):130-4. PubMed ID: 8456425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.